Zantac Unlikely To Return To The Market Soon

Ranitidine problems appear to outweigh other drugs that have elevated nitrosomine levels

Friday, April 23, 2021 - Zantac ranitidine's N-Nitrosodimethylamine (NDMA) problem appears to be more serious than the valsartan blood pressure drug or metformin diabetes drug carcinogen contamination situations. All three types of drugs have been tested by online prescription drug testing pharmacy Valisure and found to contain elevated levels of NDMA, a known carcinogen. Since the 2020 Zantac recall, scientists for drug companies and those hired by the FDA have been conducting studies into what could have been the cause of the NDMA contamination. Recently, the prestigious Memorial Sloan Kettering hospital in New York City confirmed the finding of online prescription drug testing pharmacy Valisure and found levels of NDMA "three orders of magnitude" greater than the levels of 96 NGS per tablet set by the US Food and Drug Administration (FDA). Reachers found that NDMA levels increase when ranitidine mixes with the stomach's gastric acids and causes ranitidine to degrade. The most significant element of the study according to Pharma Intelligence is that this happens along with all brands of ranitidine and is not limited to Zantac. PI tells readers: "Valisure detected NDMA in every brand and every dosage form of ranitidine that we tested whether over the counter or prescription and regardless of manufacturer," said Kaury Kucera, Valisure's chief scientific officer."

Some have speculated that it is just a matter of time before Zantac, previously the best-selling brand of heartburn medicine, would re-enter the market after its April 1, a2020 FDA recall. Because of the Sloan Memorial / Valisure study, that appears unlikely. The Sloan Memorial / Valisure study also found a link between using ranitidine Zantac and developing "breast, thyroid, bladder, and prostate cancers, while finding an inverse association among other types of cancer." As a side note, ranitidine products have been permitted to re-enter the Canadian market by Health Canada, provided companies test their products for NDMA before being offered and also while on store shelves.

This study and others are sure to provide evidence for plaintiffs that have developed cancer allegedly from using Zantac regularly and have filed antacid cancer lawsuits against Sanofi and GalaxoSmithKline, the drug's makers. Lawsuits have been organized into multidistrict litigation for many reasons, not the least of which is that a judge can hold Daubert hearings and extensively interview scientists on both sides of the Zantac NDMA argument. The judge will not decide on which expert witness is right or wrong but will judge which scientists from both sides are most credible and are allowed to be heard by juries. Ultimately, it will be up to the juries to decide the safety or risks of taking Zantac. Trials may begin in the first quarter of 2022, and the results could ignite media attention and encourage thousands of former Zantac users with cancer to file suits. Zantac plaintiffs claim to have cancer of the stomach, bladder, esophagus, prostate, colon, breast, and other forms of the disease. Zantac cancer lawyers are interviewing prospective plaintiffs in all fifty states.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.